Sequent Scientific has received an approval for acquisition of 100% stake in Tineta Pharma from its existing shareholders for a consideration to be discharged partly by cash and partly by issuance of equity shares of the Company through preferential allotment route. The object of acquisition is to enhance SeQuent’s presence in the Indian veterinary market. Consequent to acquisition, Tineta will become a wholly owned subsidiary of SeQuent Scientific. The Board of Directors of the Company at their meeting held on November 7, 2022, has considered and approved the same.
Sequent Scientific is an integrated pharmaceutical company with a global footprint headquartered in Bangalore, India which has presence in different pharmaceutical verticals including APIs, Animal Health, Analytical Services, CRAMS and specialty chemicals. Sequent is the world's largest producer of Anthelmintics and by far the strongest player in the Veterinary API business.
